EI
BMRN icon

Ellevest Inc’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ellevest Inc’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-449
Closed -$43.7K – 536
2023
Q1 		$43.7K Buy
449
+69
+18% +$7.15K ﹤0.01% 634
2022
Q4 		$39.3K Sell
380
-242
-39% -$22.7K ﹤0.01% 674
2022
Q3 		$53K Buy
622
+453
+268% +$40.3K 0.01% 562
2022
Q2 		$14K Sell
169
-121
-42% -$9.63K ﹤0.01% 816
2022
Q1 		$22K Buy
290
+82
+39% +$6.86K ﹤0.01% 717
2021
Q4 		$18K Buy
208
+36
+21% +$2.97K ﹤0.01% 734
2021
Q3 		$13K Buy
172
+61
+55% +$4.81K ﹤0.01% 767
2021
Q2 		$9K Sell
111
-85
-43% -$6.74K ﹤0.01% 777
2021
Q1 		$15K Sell
196
-254
-56% -$20.7K ﹤0.01% 711
2020
Q4 		$39K Buy
450
+333
+285% +$26.4K 0.01% 512
2020
Q3 		$9K Buy
117
+19
+19% +$1.92K ﹤0.01% 667
2020
Q2 		$12K Buy
98
+64
+188% +$6.36K ﹤0.01% 578
2020
Q1 		$3K Buy
+34
New +$2.93K ﹤0.01% 696
2019
Q3 		– Sell
-38
Closed -$3K – 513
2019
Q2 		$3K Buy
+38
New +$3.25K ﹤0.01% 314

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ellevest Inc's BMRN Position: Q2 2023 in Review

Ellevest Inc sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 449 shares — an estimated $43.7K sold.

Ellevest Inc first reported a position in BMRN in Q2 2019 and held it in 14 quarters. The position peaked at $53K in Q3 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

  • Ellevest Inc reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 449 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $43.7K.
  • Ellevest Inc first reported a position in BioMarin Pharmaceuticals in Q2 2019 and held it in 14 quarters.
  • Ellevest Inc's BioMarin Pharmaceuticals position peaked at $53K in Q3 2022.
  • 558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.